Statins Cut Heart Attacks by 30% in Adults Over 70 — But Don't Add Years of Healthy Life

The question has hung over geriatric medicine for years: should we be prescribing statins to healthy older adults who have no cardiovascular disease? The evidence base was built mostly on middle-aged populations where atherosclerosis is actively progressing and absolute risk is high enough to justify treatment. For adults over 70 — where competing risks of death, dementia, and frailty are non-trivial, and where the number of medications already tends to be high — the calculus has never been clear. STAREE, published in the New England Journal of Medicine on August 29, 2026, is the largest trial ever designed specifically to answer this question in healthy older adults.[1]

The trial enrolled 9,971 community-dwelling Australians aged 70 or older without established cardiovascular disease, type 2 diabetes, or dementia. They were randomized to atorvastatin 40 mg daily or matching placebo. The primary endpoint — deliberately chosen to capture what matters most to patients and their families — was disability-free survival, a composite of death, dementia, or persistent physical disability. After a median follow-up of 5.9 years, atorvastatin did not significantly improve disability-free survival compared with placebo. That is the headline finding, and it will give pause to clinicians who start statins in healthy elderly patients hoping to prolong functional independence.[1]

The secondary endpoint tells a different story. Major cardiovascular events — heart attack, stroke, and cardiovascular death — were reduced by approximately 30% in the atorvastatin group compared with placebo. This is a substantial relative risk reduction in a population with low baseline cardiovascular risk, and it is consistent with the well-established biology of LDL lowering. The benefit was driven predominantly by nonfatal events; the effect on cardiovascular mortality alone was not statistically significant. Muscle, liver, and diabetes-related adverse events were more frequent with atorvastatin, though serious adverse events overall occurred at an almost identical rate in both groups (2.7% vs 2.7%).[1]

Clinical Context

The statin story in the elderly has always been more complicated than in younger adults. The original JUPITER trial (2008, NEJM) enrolled participants as young as 50 and showed dramatic benefits of rosuvastatin in primary prevention, but the signal in those over 70 was less consistent. The ASPREE trial — from the same Australian infrastructure as STAREE — showed that aspirin in adults over 70 did not reduce cardiovascular events but did increase bleeding, and raised concern about a potential increase in cancer-related death, though that finding was contested.[2] STAREE was designed against this backdrop: same population, same infrastructure, different drug, different question.

The choice of disability-free survival as the primary endpoint rather than a traditional cardiovascular composite was deliberate and principled. It reflects the argument that for healthy 70-year-olds, the goal of any preventive intervention is not merely to prevent heart attacks — it is to allow people to remain independent, cognitively intact, and free of disability for as long as possible. A drug that prevents nonfatal heart attacks but does not extend disability-free life fails on this metric even if it passes on cardiovascular endpoints. STAREE essentially found that atorvastatin does both: it has real cardiovascular benefit, but that benefit does not translate to more years of independent, cognitively intact living at the population level.

Why It Matters Clinically

The disability-free survival endpoint is an argument for patient-centered medicine. It asks not "did we prevent cardiovascular events?" but "did we give you more good years?" The STAREE result suggests that at age 70 and older — in a healthy, non-diabetic, non-cardiovascular-disease population — the answer is no. The nonfatal cardiovascular events that statins prevented did not result in enough additional functional years to move the primary endpoint. This could reflect competing risks: patients who avoid a nonfatal MI may still die from cancer, frailty, or non-cardiovascular causes on a similar timeline.

The practical implication for clinicians is uncomfortable. Statins demonstrably reduce MACE in this population. But if the patient's priority is quality and independence rather than event avoidance per se, the value proposition is weaker than it appears. The deprescribing movement for statins in older adults now has a large, well-designed trial to point to. Whether to treat should increasingly be a shared decision anchored in what the patient values most — not a default to lifetime lipid-lowering.

Limitations

Australian population may not generalize to all ethnic and socioeconomic groups. The disability-free survival composite may have been underpowered for the individual components, particularly dementia. The 5.9-year follow-up, while substantial, may miss benefits of longer-term LDL lowering that accrue over decades in younger cohorts. Patients with diabetes and established CVD — who benefit most from statins — were excluded, limiting applicability to the highest-risk elderly.